Roche to take on Abbott, Dexcom with its first CGM

The new sensor is designed to last for 14 days but requires finger-stick calibration.

By Nick Paul Taylor • March 7, 2024

Dexcom receives FDA clearance for first OTC glucose sensor

The diabetes tech firm is tailoring its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin.

By Nick Paul Taylor • March 6, 2024

Dexcom, Novo Nordisk call for FDA input on digital diabetes detection devices

The companies want clarity on what evidence would be needed for new technologies to detect undiagnosed Type 2 diabetes or prediabetes.

By Nick Paul Taylor • March 4, 2024

Insulet sizes up competition as Tandem, Medtronic plan new insulin patch-pumps

Insulet CEO Jim Hollingshead said the company is “very confident” in its competitive position as rivals develop their own patch pumps.

By Elise Reuter • Feb. 29, 2024

FDA warns against using smart wearables that claim to measure blood sugar

Unauthorized smartwatches and smart rings are “manufactured by dozens of companies and sold under multiple brand names,” according to the agency.

By Nick Paul Taylor • Feb. 23, 2024

Insulet wins CE mark for integration of insulin pump with Abbott CGM

The clearance positions Insulet to sell the integrated Type 1 diabetes product in Europe beginning in the first half of the year.

By Nick Paul Taylor • Feb. 8, 2024

FDA extends deadline for comments on role of digital health in diabetes detection

The agency is seeking answers on how digital health technologies could be used in the detection of prediabetes and Type 2 diabetes.

By Nick Paul Taylor • Jan. 31, 2024

Abbott says all four segments stronger than pre-pandemic

CEO Robert Ford said investing in its base business using COVID-19 testing revenues was “absolutely the right strategy.”

By Elise Reuter • Jan. 24, 2024

3 bellwether companies to watch as medtech earnings season begins

J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports.

By Nick Paul Taylor • Jan. 22, 2024

Abbott CEO talks diabetes market, device pricing at J.P. Morgan conference

CEO Robert Ford is “very confident” in Abbott’s ability to pass $10 billion in sales of its Libre continuous glucose monitor products by 2028.

By Elise Reuter • Jan. 10, 2024

Medtronic focused on delivering durable revenue and profit growth

“Our top priority is restoring our earnings power, full stop,” CEO Geoff Martha said Monday at the J.P. Morgan Healthcare Conference.

By Susan Kelly • Jan. 9, 2024

Dexcom plans to launch new CGM this summer for people who don’t take insulin

The company also shared earnings expectations for 2024 at the J.P. Morgan Healthcare Conference.

By Elise Reuter • Jan. 9, 2024

Abbott, Tandem launch new hybrid closed-loop insulin delivery system

Competitor Medtronic also received a CE mark for a new CGM sensor that can integrate with its 780G pump.

By Elise Reuter • Jan. 8, 2024

BTIG analysts optimistic medtech will rebound in 2024 after ‘string of rough years’

Rising interest rates, fears about the impact of GLP-1 drugs and “choppy supply-chain dynamics” dragged on the industry this year, the analysts wrote.

By Nick Paul Taylor • Dec. 18, 2023

Tandem completes US launch of revamped diabetes management platform

The platform, Tandem Source, combines the features of the company’s legacy t:connect offerings with new data reports.

By Nick Paul Taylor • Dec. 15, 2023

Medtronic scraps plans to buy insulin patch-pump maker EOFlow

Medtronic cited “multiple breaches” of the companies’ agreements. EOFlow has been embroiled in patent lawsuits with Insulet this year.

By Elise Reuter • Dec. 7, 2023

Dexcom, Hologic picked to outperform in 2024: William Blair

For the medtech industry overall, the analysts wrote that procedure volume growth is likely to normalize after declining due to the COVID-19 pandemic.

By Nick Paul Taylor • Dec. 7, 2023

Unomedical recall of infusion sets tagged as Class I by FDA

The company notified Tandem Diabetes Care, its sole consignee, in October of the risk for infusion sets to detach from insulin pumps, disrupting insulin delivery.

By Nick Paul Taylor • Nov. 28, 2023

Embecta CEO Dev Kurdikar talks about growth expectations, GLP-1s

The CEO said the company’s growth expectations have not changed in the near term, even with the rise of weight loss drugs.

By Elise Reuter • Nov. 21, 2023

Abbott Diabetes Care CMO Mahmood Kazemi on expanding CGM access

Kazemi hopes anyone with diabetes will be able to access the technology, even people who don’t take insulin.

By Elise Reuter • Nov. 17, 2023

Wegovy study details revive debate over GLP-1 impact on devices

The data confirmed a cardiovascular benefit for heart patients and showed the drug could help pre-diabetic patients control their blood sugar.

By Susan Kelly • Nov. 13, 2023

NICE backs use of hybrid closed loop systems for Type 1 diabetes, if companies offer discounts

The group’s recommendation gives around 150,000 people with Type 1 diabetes living in England the chance to access the systems, according to an NHS England official.

By Nick Paul Taylor • Nov. 9, 2023

Diabetes tech firms focusing on Type 2 patients

Leaders from Abbott, Dexcom, Tandem and Insulet expect Type 2 uptake of their insulin pumps and CGMs to accelerate as coverage improves and new devices reach the market.

By Elise Reuter • Nov. 7, 2023

5 companies to watch as medtech earnings wind down

Zimmer Biomet, BD, Masimo, Illumina and Medtronic are all set to report financial results as the medtech earnings season draws to a close.

By Nick Paul Taylor • Nov. 6, 2023

Drilling down on obesity drugs: What medtech executives are saying

Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

By Susan Kelly • Nov. 2, 2023